In this study, using liver histopathological findings and clinical data from 1210 HBV patients, four noninvasive liver fibrosis models with simple calculations and clinical operability, AST/ALT, APRI, FIB-4 and gamma-glutamyl transpeptidase (GGT) to PLT ratio (GPR), were selected and applied to the evaluation of liver fibrosis in patients with CHB to verify their diagnostic efficacy and provide a basis for the clinical selection of noninvasive liver fibrosis models. The gene discussed is GGTLC1; the disease is Hepatic fibrosis.